Literature DB >> 9146581

Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma.

K S Hafez1, A C Novick, S C Campbell.   

Abstract

PURPOSE: We delineated patterns of tumor recurrence and developed guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma.
MATERIALS AND METHODS: Before December 1994, 327 patients underwent nephron sparing surgery for sporadic localized renal cell carcinoma at our clinic. Mean postoperative followup was 55.6 months. The course and outcome for patients with postoperative recurrent renal cell carcinoma were reviewed in detail.
RESULTS: Renal cell carcinoma recurred after nephron sparing surgery in 38 patients (11.6%), including 13 (4.0%) who had local tumor recurrence with (7) or without (6) metastatic disease and 25 (7.6%) who had metastatic disease without local tumor recurrence. Recurrent renal cell carcinoma was detected by associated symptoms in 25 patients and by a followup chest x-ray or abdominal computerized tomography (CT) in 13. The respective incidences of postoperative local tumor recurrence and metastatic disease according to initial pathological tumor stage were 0 and 4.4% for stage T1, 2.0 and 5.3% for stage T2, 8.2 and 11.5% for stage T3a, and 10.6 and 14.9% for stage T3b disease. The peak postoperative intervals until local tumor recurrence were 6 to 24 months (7 of 10 patients with stage T3 renal cell carcinoma) and longer than 48 months (all 3 with stage T2 disease). Patients with isolated local tumor recurrence had better survival compared to those with local tumor recurrence and metastatic disease or metastases only.
CONCLUSIONS: Followup for recurrent malignancy after nephron sparing surgery for renal cell carcinoma can be tailored according to the initial pathological tumor stage. All patients should be evaluated yearly with a medical history, physical examination and select laboratory studies. Patients with stage T1 renal cell carcinoma require no additional monitoring, while those with stage T2 disease should also undergo a yearly chest x-ray and abdominal CT every 2 years. The same recommendations are offered for patients with stage T3 renal cell carcinoma except that abdominal CT should be done every 6 months for the first 2 years postoperatively.

Entities:  

Mesh:

Year:  1997        PMID: 9146581

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  48 in total

1.  Prediction of site-specific metastases in surgically treated nonmetastatic renal cell cancer. Changes of follow-up protocol.

Authors:  I Frank; H Zincke
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma.

Authors:  Wassim Kassouf; Robert Siemens; Christopher Morash; Louis Lacombe; Michael Jewett; Larry Goldenberg; Joseph Chin; Michael Chetner; Christopher G Wood; Simon Tanguay; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

3.  Renal cell carcinoma metastasis to the ciliary body responds to proton beam radiotherapy: a case report.

Authors:  Tarek Alasil; Bahram Khazai; Lilia Loredo; Michael E Rauser
Journal:  J Med Case Rep       Date:  2011-08-03

4.  A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use.

Authors:  Christian Beisland; Gigja Guðbrandsdottir; Lars A R Reisæter; Leif Bostad; Karin M Hjelle
Journal:  World J Urol       Date:  2016-02-27       Impact factor: 4.226

5.  Low yield of surveillance imaging after surgery for T1 kidney cancer.

Authors:  Michael A Feuerstein; John E Musser; Matthew Kent; Michael Chevinsky; Eugene K Cha; Simon Kimm; William M Hilton; Daniel D Sjoberg; Timothy F Donahue; Hebert A Vargas; Jonathan A Coleman; Paul Russo
Journal:  World J Urol       Date:  2015-10-28       Impact factor: 4.226

Review 6.  [When is aftercare useful in renal cell cancer?].

Authors:  T Ebert; C Fischer
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

7.  Recurrent renal cell cancer: 10 years or more after nephrectomy.

Authors:  Emmanuel Abara; Iolanda Chivulescu; Nilam Clerk; Pablo Cano; Alexis Goth
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 8.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

9.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec

10.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.